Total synthesis of hypermodified epothilone analogs with potent in vitro antitumor activity

Organic Letters

Volumn 10, Issue 6, 2008, Pages 1183-1186

  Kuzniewski, Christian N ^a   Gertsch, Jurg ^a   Wartmann, Markus ^b   Altmann, Karl Heinz ^a  

^a ETH ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPOTHILONE DERIVATIVE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG SCREENING ASSAYS, ANTITUMOR; EPOTHILONES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE;

EID: 45549099074     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol800089x     Document Type: Article

References (43)

1. (a) Altmann, K.-H.; Gertsch, J. Nat. Prod. Rep. 2007, 24, 327-357.
2. (b) Myles, D. C. Ann. Rep. Med. Chem. 2002, 37, 125-132.
3. (c) Altmann, K.-H. Curr. Opin. Chem. Biol. 2001, 5, 424-431.
4. Jordan, M. A.; Wilson, L. Nat. Rev. Cancer 2004, 4, 253-265.
5. (a) Watkins, E. B.; Chittiboyina, A. G.; Avery, M. A. Eur. J. Org. Chem. 2006, 18, 4071-4084.
6. (b) Altmann, K.-H. Org. Biomol. Chem. 2004, 2, 2137-2152.
7. (c) Nicolaou, K. C; Ritzén, A.; Namoto, K. Chem. Commun. 2001, 1523-1535.
8. (d) Harris, C. R.; Danishefsky, S. J. J. Org. Chem. 1999, 64, 8434-8456.
9. (e) Nicolaou, K. C; Roschangar, F.; Vourloumis, D. Angew. Chem., Int. Ed. 1998, 37, 2015-2045.
10. (a) Altmann, K.-H.; Pfeiffer, B.; Arseniyadis, S.; Pratt, B. A.; Nicolaou, K. C. ChemMedChem 2007, 2, 396-423.
11. (b) Höfle, G.; Reichenbach, H. Anticancer Agents from Natural Products; CRC Press: Boca Raton, 2005; pp 413-450.
12. Larkin, J. M. G.; Kaye, S. B. Expert Opin. Invest. Drugs 2006, 15, 691-702.
13. Altmann, K.-H. Curr. Pharm. Design 2005, 11, 1595-1613.
14. http://www.cancer.gov/cancertopics/druginfo/fda-ixabepilone.
15. (a) Alhamadsheh, M. M; Gupta, S.; Hudson, R. A.; Perera, L.; Tillekeratne, L. M. V. Chem. Eur. J. 2008, 14, 570-581.
16. (b) Alhamadsheh, M. M.; Hudson, R. A.; Tillekeratne, L. M. V. Org. Lett. 2006, 8, 685-688.
17. (c) Winkler, J. D.; Holland, J. M.; Kasparec, J.; Axelsen, P. H. Tetrahedron 1999, 55, 8199-8214.
18. (a) Feyen, F.; Cachoux, F.; Gertsch, J.; Wartmann, M.; Altmann, K.-H. Acc. Chem. Res. 2008, 41, 21-31.
19. (b) Feyen, F.; Gertsch, J.; Wartmann, M.; Altmann, K.-H. Angew. Chem., Int. Ed. 2006, 45, 5880-5885.
20. (c) Cachoux, F.; Isarno, T.; Wartmann, M.; Altmann, K.-H. Angew. Chem., Int. Ed. 2005, 44, 7469-7473.
21. (d) Cachoux, F.; Schaal, F.; Teichert, A.; Wagner, T.; Altmann, K.-H. Synlett 2004, 2709-2712.
22. (a) Nicolaou, K. C.; Sasmal, P. K.; Rassias, G.; Reddy, M. V.; Altmann, K.-H.; Wartmann, M.; O'Brate, A.; Giannakakou, P. Angew. Chem., Int. Ed. 2003, 42, 3515- 3520.
23. (b) Nicolaou, K. C.; Namoto, K.; Ritzén, A.; Ulven, T.; Shoji, M.; Li, J.; D'Amico, G.; Liotta, D.; French, C. T.; Wartmann, M.; Altmann, K.-H.; Giannakakou, P. J. Am. Chem. Soc. 2001, 123, 9313-9323.
24. (c) Nicolaou, K. C.; Namoto, K.; Li, J.; Ritzen, A.; Ulven, T.; Shoji, M.; Zaharevitz, D.; Gussio, R.; Sackett, D. L.; Ward, R. D.; Hensler, A.; Fojo, T.; Giannakakou, P. Chembiochem 2001, 2, 69-75.
25. (d) Johnson, J.; Kim, S. H.; Bifano, M.; DiMarco, J.; Fairchild, C.; Gougoutas, J.; Lee, F.; Long, B.; Tokarski, J.; Vite, G. Org. Lett. 2000, 2, 1537-1540.
26. For 9,10-dehydro-epothilones, see: (a) Chou, T. C.; Dong, H. J.; Zhang, X. G.; Tong, W. P.; Danishefsky, S. J. Cancer Res. 2005, 65, 9445-9454.
27. (b) Rivkin, A.; Yoshimura, F.; Gabarda, A. E.; Cho, Y. S.; Chou, T. C.; Dong, H. J.; Danishefsky, S. J. J. Am. Chem. Soc. 2004, 126, 10913-10922.
28. (c) Yoshimura, F.; Rivkin, A.; Gabarda, A. E.; Chou, T. C.; Dong, H. J.; Sukenick, G.; Morel, F. F.; Taylor, R. E.; Danishefsky, S. J. Angew. Chem., Int. Ed. 2003, 42, 2518-2521.
29. (d) Rivkin, A.; Yoshimura, F.; Gabarda, A. E.; Chou, T. C.; Dong, H. J.; Tong, W. P.; Danishefsky, S. J. J. Am. Chem. Soc. 2003, 125, 2899-2901.
30. (e) Chou, T. C.; Dong, H. J.; Rivkin, A.; Yoshimura, F.; Gabarda, A. E.; Cho, Y. S.; Tong, W. P.; Danishefsky, S. J. Angew. Chem., Int. Ed. 2003, 42, 4761-4767.
31. Walkup, R. D.; Kahl, J. D.; Kane, R. R. J. Org. Chem. 1998, 63, 9113-9116.
32. Brown, H. C.; Ramachandran, P. V. J. Organomet. Chem. 1995, 500, 1-19.
33. Charette, A. B.; Juteau, H.; Lebel, H.; Molinaro, C. J. Am. Chem. Soc. 1998, 120, 11943-11952.
34. Dale, J. A.; Mosher, H. S. J. Am. Chem. Soc. 1973, 95, 512-519.
35. Griffith, W. P.; Ley, S. V.; Whitcombe, G. P.; White, A. D. J. Chem. Soc., Chem. Commun. 1987, 1625-1627.
36. No diastereomeric impurities arising from incomplete stereoselec-tivity of the cyclopropanation reaction were detectable by 400 MHz NMR-spectroscopy. This assessment is based on the NMR-spectral comparison between 18 and the cyclopropanation product obtained from 17 in the presence of (-)-dioxaborolane ent-24.
37. Barrett, A. G. M.; Tam, W. J. Org. Chem. 1997, 62, 7673-7678.
38. He, R.; Deng, M. Z. Tetrahedron 2002, 58, 7613-7617.
39. (a) Grieco, P. A.; Gilman, S.; Nishizawa, M. J. Org. Chem. 1976, 41, 1485-1486.
40. (b) Sharpless, K. B.; Young, M. W. J. Org. Chem. 1975, 40, 947-949.
41. Hamel, E.; del Campo, A. A.; Lustbader, J.; Lin, C. M. Biochemistry 1983, 22, 1271-1279.
42. (a) Meyer, T.; Regenass, U.; Fabbro, D.; Alteri, E.; Rösel, J.; Müller, M.; Caravatti, G.; Matter, A. Int. J. Cancer 1989, 43, 851-856.
43. (b) Nicolaou, K. C.; Scarpelli, R.; Bollbuck, B.; Werschkun, B.; Pereira, M. M.; Wartmann, M.; Altmann, K.-H.; Zaharevitz, D.; Gussio, R.; Gianna-kakou, P. Chem. Biol. 2000, 7, 593-599.